Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Case Report
  • Published:

Complete resolution of severe chronic active Epstein–Barr virus infection by cultured, activated donor T lymphocyte infusion after nonmyeloablative stem cells allografting

Bone Marrow Transplantation volume 32, pages 107–110 (2003)Cite this article

Summary:

A patient with chronic active Epstein–Barr virus (EBV) infection was treated by allogeneic SCT from an HLA-identical sibling donor, using a nonmyeloablative regimen. Even on day 70, mixed chimerism remained together with a quite high viral load. On days 76 and 90, donor lymphocytes were infused after short-term culture with OKT3 plus recombinant IL-2. At 8 days after the last dose, all hematopoietic cells were shown to be donor-type dominant; thereafter, the viral load started to decrease and finally disappeared. Anti-mHA-specific CTLs were generated in vitro, which were shown to be effective in eradicate viral-infected recipient T lymphocytes.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Okamura T, Hatsukawa Y, Arai H et al. Blood stem-cell transplantation for chronic active Epstein–Barr virus with lymphoproliferation. Lancet 2000; 356: 223–224.

    Article  CAS  Google Scholar 

  2. Fujii N, Takenaka K, Hiraki A et al. Allogeneic peripheral blood stem cell transplantation for the treatment of chronic active Epstein–Barr virus infection. Bone Marrow Transplant 2000; 26: 805–808.

    Article  CAS  Google Scholar 

  3. Kimura H, Hoshino Y, Kanegane H et al. Clinical and virologic characteristics of chronic active Epstein–Barr virus infection. Blood 2001; 98: 280–286.

    Article  CAS  Google Scholar 

  4. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–763.

    CAS  Google Scholar 

  5. Straus SE . The chronic mononucleosis syndrome. J Infect Dis 1988; 157: 405–412.

    Article  CAS  Google Scholar 

  6. Okano M, Matsumoto S, Osato T et al. Severe chronic active Epstein–Barr virus infection syndrome. Clin Microbiol Rev 1991; 4: 129–135.

    Article  CAS  Google Scholar 

  7. Ohga S, Nomura A, Takada H et al. Epstein–Barr virus (EBV) load and cytokine gene expression in activated T cells of chronic active EBV infection. J Infect Dis 2001; 183: 1–7.

    Article  CAS  Google Scholar 

  8. Falkenburg JH, Goselink HM, van der Harst D et al. Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Exp Med 1991; 174: 27–33.

    Article  CAS  Google Scholar 

  9. Quintanilla-Martinez L, Kumar S, Fend F et al. Fulminant EBV(+) T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome. Blood 2000; 96: 443–451.

    CAS  PubMed  Google Scholar 

  10. Rodriguez J, Romaguera JE, Manning J et al. Nasal-type T/NK lymphomas: a clinicopathologic study of 13 cases. Leuk Lymphoma 2000; 39: 139–144.

    Article  CAS  Google Scholar 

  11. Ballen KK, Becker PS, Emmons RV et al. Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy. Blood 2002; 100: 442–450.

    Article  CAS  Google Scholar 

  12. Takayama T, Sekine T, Makuuchi M et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356: 802–807.

    Article  CAS  Google Scholar 

  13. Azuma H, Yamada Y, Shibuya-Fujiwara N et al. Functional evaluation of ex vivo expanded cord blood lymphocytes. Possible use for adoptive cellular immunotherapy. Exp Hematol 2002; 30: 346–351.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We are indebted to Mr Osamu Hyodo, Ms Fumiko Tsuchida, Ms Akiko Tanabe for their continuous support of the study (examination of the patient's samples).

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, Tokai University School of Medicine, Kanagawa, Japan

    F Yoshiba, M Hagihara, K Tazume, Y Ogawa, K Kishi & T Hotta

  2. Institute of Medical Science, Tokai University School of Medicine, Kanagawa, Japan

    A Higuchi & S Kato

Authors
  1. F Yoshiba
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Hagihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Tazume
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y Ogawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K Kishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Higuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T Hotta
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yoshiba, F., Hagihara, M., Tazume, K. et al. Complete resolution of severe chronic active Epstein–Barr virus infection by cultured, activated donor T lymphocyte infusion after nonmyeloablative stem cells allografting. Bone Marrow Transplant 32, 107–110 (2003). https://doi.org/10.1038/sj.bmt.1704074

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704074

Keywords

This article is cited by

Search

Advanced search

Quick links